StrataXRT vs. Standard Clinical Practice in the Prevention and Treatment of Radiation Dermatitis

Inclusion Criteria: * Patients with cancer undergoing a curative course of radiation therapy using standard protocols to the following cancer sites: * Head and neck cancers receiving \>= 60Gy who are not receiving concurrent Cetuximab * Intact breast receiving \>= 40Gy (includes patients receiving boost fields using photon or elections) * Post-mastectomy chest wall (breast cancer diagnosis only) receiving \>= 50Gy * Gynaecological cancers requiring whole pelvis irradiation receiving \>= 45Gy * Skin cancers to the axilla/groin regions receiving \>= 40Gy * Male and female patients \>18 years of age * Patients who do not have a known allergy to silicon * Patients who are able to attend the four post-treatment weekly skin assessment appointments Exclusion Criteria: Ineligible participants are patients undergoing a course of curative radiation therapy: * Who are participating in another interventional study * With an allergy to product content (standard or StrataXRT) * With an existing skin rash, ulceration or open wound in the treatment area * With a pre-existing systemic skin disease (dermatological conditions, connective tissue disorders) * Who have had previous radiation therapy to the current treatment area * Who are on immuno-suppression drugs